
|Videos|February 11, 2019
Expert Explains the Greatest Challenge in Treating Patients With MDS and AML
Author(s)Christopher R. Cogle, MD
Christopher R. Cogle, MD, a professor of medicine at the University of Florida, discusses the greatest challenge in treating patients with myelodysplastic syndromes and acute myeloid leukemia.
Advertisement
Christopher R. Cogle, MD, a professor of medicine at the University of Florida, discusses the greatest challenge in treating patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Both MDS and AML are very heterogenous diseases where a patient has multiple MDS or AML clones, Cogle says. In his research, he found that there were hundreds of genomic abnormalities in each patient.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5








































